OTLK - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics Inc. (OTLK) | Benzinga

LOS ANGELES, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ:OTLK) securities between December 29, 2022 and August 29, 2023, inclusive (the "Class Period").

If you suffered a loss on your Outlook investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Outlook-Therapeutics-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On August 30, 2023, Outlook disclosed that the FDA had issued a complete response letter regarding the Company's wet age-related macular degeneration ("wet AMD") treatment, ONS-5010. The FDA concluded that "it could not approve the [biologics license application]" ...

OTLK)>Full story available on Benzinga.com